MedTrace Logo

--SuPERIOR Trial--

NCT06191250 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-02-03

No results posted yet for this study

Summary

The Window-of-Opportunity (WOO) Network is a collaboration among Ontario's doctors and scientists to conduct clinical trials in newly-diagnosed cancer patients before they have surgery with an initial focus on understanding how cancer drugs can impact the immune system.

There is often a waiting period of two to six weeks between when a patient first receives a cancer diagnosis and their scheduled surgery. This period provides a unique opportunity to study tumours before they are treated, allowing scientists to explore new ways to identify cancer, measure how cancer cells respond to treatment, and understand how therapies work. WOO Network trials include drugs or treatments that already have been tested in other clinical trials or are already approved by Health Canada.

The SuPERIOR trial is a WOO trial and it is designed for cohort of patients patients diagnosed with newly-diagnosed cancer patients with stage two or three non-small cell lung cancer.

The patients who are enrolled in this trial will received combination of Non-ablative oligofractionated radiation (NORT) which is a low dose of radiation and one dose of Durvalumab, an immunotherapy drug before their surgery.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)
  • Clinical Staging T2b-3 N0-1 M0

Interventions

DRUG

Durvalumab

one dose of durvalumab (750 mg IV)

RADIATION

Non-ablative oligofractionated radiation (NORT)

12 Gy of Radiation in 3 fractions

Sponsors & Collaborators

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Marc de Perrot, MD, MSc, FRCSC · Toronto General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-28
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06191250 on ClinicalTrials.gov